Millennium Management LLC Decreases Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Millennium Management LLC lowered its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 94.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,498 shares of the company's stock after selling 134,587 shares during the period. Millennium Management LLC's holdings in CRISPR Therapeutics were worth $334,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. First Horizon Advisors Inc. increased its position in CRISPR Therapeutics by 33.4% during the fourth quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company's stock worth $80,000 after acquiring an additional 511 shares during the period. Elkhorn Partners Limited Partnership increased its holdings in shares of CRISPR Therapeutics by 22.6% during the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,800 shares of the company's stock worth $150,000 after buying an additional 700 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in CRISPR Therapeutics by 34.2% in the 4th quarter. Farther Finance Advisors LLC now owns 3,834 shares of the company's stock valued at $151,000 after buying an additional 977 shares during the last quarter. Whipplewood Advisors LLC acquired a new position in CRISPR Therapeutics during the 4th quarter worth about $159,000. Finally, PNC Financial Services Group Inc. boosted its holdings in CRISPR Therapeutics by 16.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,346 shares of the company's stock valued at $171,000 after acquiring an additional 606 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the business's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the transaction, the insider now owns 6,068 shares of the company's stock, valued at $218,083.92. The trade was a 39.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is currently owned by insiders.

CRISPR Therapeutics Trading Down 1.8%

Shares of CRISPR Therapeutics stock traded down $0.73 during trading on Thursday, hitting $40.79. The stock had a trading volume of 773,606 shares, compared to its average volume of 1,750,288. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $67.88. The firm has a market cap of $3.52 billion, a price-to-earnings ratio of -9.33 and a beta of 1.75. The business's 50-day moving average is $37.37 and its 200 day moving average is $41.07.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The business's quarterly revenue was up 71.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.43) earnings per share. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, May 20th. Royal Bank of Canada lowered their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a research report on Wednesday, February 12th. Citigroup lowered their target price on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research note on Tuesday, February 18th. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective on the stock in a research report on Wednesday, February 12th. Finally, Barclays reduced their target price on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.